In view of the above outcomes, the contribution of circulating Nrg4 in the development of NAFLD requires further verification in prospective cohort studies with larger sample sizes in order to adequately explore its role as a risk biomarker. The gene discussed is NRG4; the disease is metabolic dysfunction-associated steatotic liver disease.